Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

(2010) M. A. Nauck et al.   DIABETOLOGIA

Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes

(2010) Soushou LEE et al.   ENDOCRINE JOURNAL

Pioglitazone: side effect and safety profile

(2010) Priya Shah et al.   Expert Opinion On Drug Safety

Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

(2010) et al.   Journal of Diabetes Investigation

GIP and GLP-1, the two incretin hormones: Similarities and differences

(2010) Yutaka Seino et al.   Journal of Diabetes Investigation

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

(2010) Daisuke Yabe et al.   Journal of Diabetes Investigation

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events

(2009) Bo Ahrén   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus

(2009) L. BLONDE   CLEVELAND CLINIC JOURNAL OF MEDICINE

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2009) Richard E. Pratley et al.   CURRENT MEDICAL RESEARCH AND OPINION

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

(2009) R. E. Pratley et al.   DIABETES OBESITY & METABOLISM

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

(2009) Richard E Pratley   EXPERT OPINION ON PHARMACOTHERAPY

Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone

(2009) Priscilla Hollander et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies

(2009) R. Keith Campbell   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Fate of the beta-cell in the pathophysiology of type 2 diabetes

(2009) R. Keith Campbell   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

(2008) R. A. DeFronzo et al.   DIABETES CARE

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

(2008) M. A. Nauck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE